MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine
MIRA Pharmaceuticals shares soared over 100% to $2.74 in pre-market trading Oct. 16 after preclinical data showed its oral drug Mira-55 outperformed injected morphine in animal pain studies. The company plans to file for human trials. Social media activity spiked, but analysts remain divided, with one “Sell” rating and others projecting targets above $10.
